Current Opinion in Supportive and Palliative Care was launched in 2007. It is one of a successful series of review journals whose unique format is designed to provide a systematic and critical assessment of the literature as presented in the many primary journals. The fields of supportive and palliative care are divided into 12 sections that are reviewed once a year. Each section is assigned a Section Editor, a leading authority in the area, who identifies the most important topics at that time. Here we are pleased to introduce the Journal's Section Editors for this issue.
Dr Fred Saad obtained his medical degree in 1985 from the University of Montreal, Canada and then completed his residency in urology in 1990. He completed a Fellowship in Urologic Oncology in 1992 and became Chief of Urology at Notre-Dame Hospital of the University of Montreal in 1994. Dr Saad established the urologic oncology clinic and research center at the University of Montreal. He is currently Director of Urologic Oncology and is Director of the Prostate Cancer Research Lab of the Montreal Cancer Institute. In 2004 he was awarded the first Chair in Prostate Cancer at the University of Montreal.
Dr Saad is Professor of Surgery/Urology at the University of Montreal. He was President of the Quebec Urologic Association from 2001 to 2003. He is Chairman of the National Cancer Institute of Canada (NCIC) GU group and the Canadian Uro-Oncology Group and is secretary of the Canadian Prostate Health Council as well as the GU Global. He sits on nine editorial boards and serves as a reviewer for over 30 urology and oncology journals. He has authored/co-authored over 150 peer reviewed articles, 500 scientific abstracts and 15 book chapters. He has been an invited speaker/professor over 200 times in over 20 different countries.
His main research interests include molecular prognostic markers in prostate cancer and new therapeutic approaches to hormone-refractory prostate cancer. Presently he coordinates over 30 clinical and basic research projects in urologic oncology.
Dr Allan Lipton is Professor of Medicine and Oncology at the M.S. Hershey Medical Center in Hershey, Pennsylvania, USA. Dr Lipton has a longstanding interest in the natural history and treatment of bone metastases. His group was the first in the US to treat a patient with pamidronate for bone metastases and also the first in the world to treat patients with zoledronic acid.
James R. Berenson
Dr Berenson has specialized in research related to myeloma and metastatic bone disease both in the basic and clinical areas for more than 20 years. He has been involved in many of the major breakthroughs that have brought new treatments for patients with these diseases resulting in both an improvement in the length and quality of their lives.
He serves as a member of the National Institutes of Health–Center for Scientific Review, Clinical Oncology Study Section. He is a member of the Scientific Boards of the Multiple Myeloma Research Foundation and the International Myeloma Foundation. He serves on both the Foundation and the Scientific Boards of the Leukemia, Lymphoma and Myeloma Society. He also works with many other groups known for their work in multiple myeloma and bone metastases.
After receiving a Bachelor of Science with Distinction from Stanford University, he earned his Doctorate in Medicine from the University of California at San Diego. Dr Berenson completed his internship and residency in internal medicine at the University of Utah Medical Center and fellowships in hematology/oncology at the University of California at Los Angeles (UCLA). He is certified by the American Board of Internal Medicine in both internal medicine and medical oncology. He has been affiliated most recently with Cedars–Sinai Medical Center in Los Angeles and served as the Director of the Multiple Myeloma and Bone Metastasis Programs in the Department of Medicine, Division of Hematology/Oncology. Dr Berenson has performed research as a member of the Departments of Medicine and Biological Chemistry at the UCLA School of Medicine and has served as Chief of Medical Oncology and Cancer Research as well as Director of Research at the Greater Los Angeles Veterans Administration Healthcare Systems. Dr Berenson has authored and co-authored numerous books, articles, and abstracts in journals including Blood, Cancer, Cancer Research, Journal of Clinical Investigation, Journal of Clinical Oncology, New England Journal of Medicine, and Science.
In addition to his research interests in myeloma and metastatic bone disease, he also studies antibodies, T-cell receptors, cytokines, cancer genes, viruses and blood vessel development. Dr Berenson has also conducted numerous clinical trials related to the treatment of multiple myeloma and metastatic bone disease. Because he is internationally known for his expertise and accomplishments in these areas, he has also been asked to give numerous lectures and organize many meetings both nationally and internationally.
Dr Berenson has a private practice which specializes in the treatment of patients with myeloma and metastatic bone disease. He is also President and Chief Executive Officer of Oncotherapeutics, Inc., a corporation that conducts clinical trials related to myeloma and metastatic bone disease as well as other cancers throughout the United States.
Dr Diana Greenfield is Macmillan Consultant Nurse & Clinical Lead in Survivorship and Late Effects at Sheffield Teaching Hospitals NHS Foundation Trust, and Honorary Senior Lecturer within the Academic Unit of Clinical Oncology, University of Sheffield, UK. Clinically, Diana runs the Teenage and Young Adult Late Effects Multi-disciplinary Team and provides late effects care including survivors of childhood and adolescent cancers in nurse-led clinics. Diana works to develop a long-term follow-up strategy and clinical service initiatives for patients who have recovered/ or are in remission from cancer within her Trust. Academically, her research interests include the long-term follow-up of cancer survivors, such as return to work issues and models of follow-up care; and the physical late effects of cancer therapy such as metabolic syndrome and hypogonadism. Diana is a member of: the Consequences of Cancer Treatment Collaborative (CCaT), funded through the National Cancer Survivorship Initiative; the European Blood and Marrow Transplantation Late Effects Working Party; the Society for Endocrinology, Late Effects Special Interest Group. Diana is on the editorial board of the Journal of Cancer Survivorship.
Dr Lars Hjorth is a Consultant in Paediatric Oncology at Skåne University Hospital, Lund, Sweden and a Scientist at the Faculty of Medicine at Lund University, Lund, Sweden. He holds a PhD in Paediatric Oncology. Dr Hjorth is the former head of the Division of Paediatric Oncology in Lund and former head of the Swedish Working Group for Long-term Follow-up after Childhood Cancer (SALUB). He is the Chairperson for the Pan-European Network for Care of Survivors after Childhood and Adolescent Cancer (PanCare) and Coordinator for the EU-project PanCare Childhood and Adolescent Cancer Survivor Care and Follow-up Studies (PanCareSurFup, Grant agreement number 257505).
Dr Hjorth has a research interest in late effects after treatment for childhood and adolescent cancer, long-term follow-up, nephrotoxicity, bone sarcomas and quality of life. He holds grants from the Seventh Framework Programme of the European Union and the Swedish Childhood Cancer Foundation. Dr Hjorth has published in peer-reviewed journals and written two book chapters. He is a frequent speaker at international meetings.